Login / Signup

Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: insights from a prospective IgG4-related disease registry.

Ji ZongfeiZhang LijuanSun YingLiu DongmeiWu SifanKong XiufangMa LingyingLiu YunMa LiliChen HuiyongXiufang Kong
Published in: Therapeutic advances in chronic disease (2021)
Tocilizumab could be a better steroid-sparing agent, with a comparable curative effect and tolerance, than CYC, in the treatment of IgG4-RD.
Keyphrases
  • rheumatoid arthritis
  • juvenile idiopathic arthritis
  • rheumatoid arthritis patients
  • low dose
  • high dose
  • rectal cancer
  • systemic lupus erythematosus
  • minimally invasive
  • prognostic factors
  • disease activity